Register Login
Register to leave comments
  • News bot Jan. 30, 2026, 8:13 a.m.

    📋 Esperion Therapeutics Inc (ESPR) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 08:00:54

    Event Type: Clinical Trial Update

    Event Details:

    Esperion Therapeutics Inc (ESPR) Announces Clinical Trial Update Esperion Therapeutics Inc (ESPR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: results, expectations
    • Diseases/Conditions: Esperion’s history
    • Collaboration: GLOBE NEWSWIRE
    • Updated Timeline: Year-End 2025, the full-year 2025
      • expected in 2026

    🔬 Clinical Development Pipeline (Esperion Therapeutics Inc):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE3 Inflammation ClinicalTrials.gov
    Statin Therapy DRUG Phase PHASE2 Hypercholesterolemia ClinicalTrials.gov
    bempedoic acid 180mg DRUG Phase PHASE2 Hypercholesterolemia ClinicalTrials.gov
    TDM-105795 topical vehicle solution DRUG Phase PHASE2 Alopecia, Androgenetic ClinicalTrials.gov
    TDM-105795, 0.02% DRUG Phase PHASE2 Alopecia, Androgenetic ClinicalTrials.gov
    TDM-105795, 0.0025% DRUG Phase PHASE2 Alopecia, Androgenetic ClinicalTrials.gov
    Placecbo DRUG Phase PHASE2 Restless Leg Syndrome ClinicalTrials.gov
    BRC-002 DRUG Phase PHASE2 Restless Leg Syndrome ClinicalTrials.gov
    Computer Alert BEHAVIORAL Approved Peripheral Artery Disease ClinicalTrials.gov
    Difluprednate Ophthalmic Emulsion DRUG Phase PHASE2 Anterior Uveitis ClinicalTrials.gov
    cyclosporine A DRUG Phase PHASE3 Dry Eye Syndromes ClinicalTrials.gov
    Fenretinide DRUG Phase PHASE2 Geographic Atrophy ClinicalTrials.gov
    Prednisolone Acetate DRUG Phase PHASE3 Uveitis ClinicalTrials.gov
    Difluprednate DRUG Phase PHASE3 Uveitis ClinicalTrials.gov
    cyclosporine DRUG Phase PHASE3 Dry Eye Syndromes ClinicalTrials.gov
    Prednisolone acetate 1% DRUG Phase PHASE4 Cataracts ClinicalTrials.gov
    Difluprednate ophthalmic emulsion 0.05% DRUG Phase PHASE4 Cataracts ClinicalTrials.gov
    evolocumab DRUG Phase PHASE2 Hypercholesterolemia ClinicalTrials.gov
    ETC-1002 DRUG Phase PHASE2 Hypercholesterolemia ClinicalTrials.gov
    Atorvastatin DRUG Phase PHASE2 Hypercholesterolemia ClinicalTrials.gov
    bempedoic acid DRUG Phase PHASE3 Hypercholesterolemia ClinicalTrials.gov
    Placebos DRUG Phase PHASE3 Hyperlipidemias ClinicalTrials.gov
    Ezetimibe DRUG Phase PHASE3 Hyperlipidemias ClinicalTrials.gov
    [14C-ETC-1002] DRUG Phase PHASE1 Hyperlipidemia ClinicalTrials.gov
    ETC-1002 or placebo DRUG Phase PHASE1 Mild Dyslipidemia ClinicalTrials.gov
    Atorvastatin 20mg DRUG Phase PHASE2 Hypercholesterolemia ClinicalTrials.gov
    Ezetimibe 10mg DRUG Phase PHASE2 Hypercholesterolemia ClinicalTrials.gov
    Placebo oral capsule DRUG Phase PHASE2 Diabetes ClinicalTrials.gov
    Placebo Oral Tablet DRUG Phase PHASE2 Diabetes ClinicalTrials.gov
    Ezetimibe 10 mg Oral Tablet DRUG Phase PHASE2 Diabetes ClinicalTrials.gov
    Bempedoic acid + Ezetimibe FDC Oral Tablet DRUG Phase PHASE2 Diabetes ClinicalTrials.gov
    botulinum toxin, Type A BIOLOGICAL Phase PHASE2 Lateral Canthal Lines ClinicalTrials.gov
    Vehicle BIOLOGICAL Phase PHASE2 Lateral Canthal Lines ClinicalTrials.gov
    Bempedoic Acid / Ezetimibe Oral Tablet DRUG Phase PHASE4 Cardiovascular Diseases ClinicalTrials.gov
    Bempedoic Acid / Ezetimibe DRUG Preclinical Pregnancy ClinicalTrials.gov
    Matching placebo tablet DRUG Phase PHASE3 Cardiovascular Diseases ClinicalTrials.gov
    Bempedoic acid 180 mg tablet DRUG Phase PHASE3 Cardiovascular Diseases ClinicalTrials.gov
    Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet DRUG Phase PHASE4 Healthy Lactating Women ClinicalTrials.gov
    Bempedoic Acid 180 MG Oral Tablet DRUG Phase PHASE4 Healthy Lactating Women ClinicalTrials.gov
    AI-09 BIOLOGICAL Phase PHASE1 Glabellar Frown Lines ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Esperion Therapeutics Inc
    • Ticker Symbol: ESPR

Search

News categories